Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexza's Inhaled Antipsychotic To Get Indication-Limiting REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm's proposed risk management plan may exclude patients with COPD or asthma. The application for AZ-004 is expected to be resubmitted by July, with an advisory committee likely by year end.
Advertisement

Related Content

Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
FDA Cmte. To Scrutinize Pulmonary Safety, REMS For Alexza's Inhaled Antipsychotic
FDA Cmte. To Scrutinize Pulmonary Safety, REMS For Alexza's Inhaled Antipsychotic
Tax Benefits Highlight Announced Merger Of Valeant And Biovail
Biovail Partners with Alexza On Late-Stage CNS Drug For Schizophrenia Agitation
Biovail Partners with Alexza On Late-Stage CNS Drug For Schizophrenia Agitation

Topics

Advertisement
UsernamePublicRestriction

Register

PS071703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel